LTR Pharma (ASX:LTP) Total Equity: A$26.87 Mil (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.56
! 1 Warning Sign
View Full Analysis

What is LTR Pharma Total Equity?

LTR Pharma ASX:LTP -4.27% 15 Total Equity is A$26.87 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

LTR Pharma's total equity for the quarter that ended in Dec. 2025 was A$26.87 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

LTR Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Total Equity Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
-0.04 1.77 7.49 2.94 31.51

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial 6.28 2.94 34.30 31.51 26.87
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

LTR Pharma's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=32.211-0.701
=31.51

LTR Pharma's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=27.323-0.458
=26.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$26.87 Mil mean?
LTR Pharma (ASX:LTP) has a Total Equity of A$26.87 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for LTR Pharma and its competitors.
Is LTR Pharma's Total Equity too high?
LTR Pharma's current Total Equity is A$26.87 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Total Equity compare to VRTX and REGN?
LTR Pharma's Total Equity of A$26.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for LTR Pharma and its competitors. LTR Pharma's current Total Equity is A$26.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Total Equity of A$26.87 Mil. The current Total Equity is A$26.87 Mil. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Total Equity is A$26.87 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price